IN2014KN01772A - - Google Patents

Info

Publication number
IN2014KN01772A
IN2014KN01772A IN1772KON2014A IN2014KN01772A IN 2014KN01772 A IN2014KN01772 A IN 2014KN01772A IN 1772KON2014 A IN1772KON2014 A IN 1772KON2014A IN 2014KN01772 A IN2014KN01772 A IN 2014KN01772A
Authority
IN
India
Prior art keywords
treatment
inhibitor
combination
relates
present
Prior art date
Application number
Inventor
Deric L Wheeler
Thore Hettmann
Original Assignee
U3 Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U3 Pharma Gmbh filed Critical U3 Pharma Gmbh
Publication of IN2014KN01772A publication Critical patent/IN2014KN01772A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Abstract

The present invention relates to the use of an inhibitor of HER 3 for the treatment of a hyperproliferative disease in combination with radiation treatment.
IN1772KON2014 2012-02-23 2013-02-22 IN2014KN01772A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261602239P 2012-02-23 2012-02-23
PCT/EP2013/053562 WO2013124419A1 (en) 2012-02-23 2013-02-22 Her3 inhibitor for modulating radiosensitivity

Publications (1)

Publication Number Publication Date
IN2014KN01772A true IN2014KN01772A (en) 2015-10-23

Family

ID=47749820

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1772KON2014 IN2014KN01772A (en) 2012-02-23 2013-02-22

Country Status (11)

Country Link
US (2) US10357566B2 (en)
EP (1) EP2817340B1 (en)
JP (2) JP6207531B2 (en)
KR (1) KR102051505B1 (en)
CN (2) CN108404129A (en)
BR (1) BR112014020666A2 (en)
CA (1) CA2865256C (en)
ES (1) ES2842201T3 (en)
HK (1) HK1199044A1 (en)
IN (1) IN2014KN01772A (en)
WO (1) WO2013124419A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102316892B1 (en) * 2019-12-20 2021-10-27 주식회사 베르티스 A Composition for Diagnosing Cancer
KR20210095781A (en) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 A multi-specific antibody comprising a fusion construct consisting of a Fab and a bioactive effector moiety

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
SG50585A1 (en) * 1990-01-18 1998-07-20 Cura Nominees Pty Ltd Glycoalkaloids
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
KR20010071271A (en) * 1998-05-15 2001-07-28 존 비. 랜디스 Treatment of Human Tumors with Radiation and Inhibitors of Growth Factor Receptor Tyrosine Kinases
US20050239738A1 (en) * 2000-11-17 2005-10-27 Rupert Schmidt-Ullrich Genetic inhibition of epidermal growth factor receptor function and carcinoma cell radiosensitization
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
AR056857A1 (en) * 2005-12-30 2007-10-24 U3 Pharma Ag DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES
ATE532519T1 (en) * 2006-01-06 2011-11-15 Geistlich Soehne Ag RADIATED COMPOSITIONS AND TREATMENT OF CANCER USING RADIATION IN COMBINATION WITH TAUROLIDINE AND/OR TAURULTAM
US7838495B2 (en) * 2007-04-27 2010-11-23 University Of Maryland, Baltimore Compositions and methods of use of EPB1, and ErbB3 binding protein
EP2138511A1 (en) * 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 as a determinant for the prognosis of melanoma
US8139714B1 (en) * 2009-06-25 2012-03-20 Velayudhan Sahadevan Few seconds beam on time, breathing synchronized image guided all fields simultaneous radiation therapy combined with hyperthermia
ES2655737T3 (en) 2009-11-13 2018-02-21 Daiichi Sankyo Europe Gmbh Materials and methods to treat or prevent diseases associated with HER-3

Also Published As

Publication number Publication date
US10357566B2 (en) 2019-07-23
US20150017096A1 (en) 2015-01-15
EP2817340A1 (en) 2014-12-31
JP2017165711A (en) 2017-09-21
EP2817340B1 (en) 2020-12-09
CN108404129A (en) 2018-08-17
HK1199044A1 (en) 2015-06-19
JP2015509944A (en) 2015-04-02
JP6368811B2 (en) 2018-08-01
KR20140123544A (en) 2014-10-22
KR102051505B1 (en) 2019-12-03
BR112014020666A2 (en) 2018-09-25
ES2842201T3 (en) 2021-07-13
JP6207531B2 (en) 2017-10-04
CA2865256A1 (en) 2013-08-29
WO2013124419A1 (en) 2013-08-29
CN104136464A (en) 2014-11-05
US20190388540A1 (en) 2019-12-26
CA2865256C (en) 2020-02-11
US11351259B2 (en) 2022-06-07

Similar Documents

Publication Publication Date Title
HK1207861A1 (en) Substituted cycloalkenopyrazoles as bub1 inhibitors for the treatment of cancer bub1
IL231591A0 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
IL263661A (en) Combination therapy for the treatment of glioblastoma
MX356728B (en) Pharmaceutical combination for use in the treatment of diabetes type 2.
PT3400943T (en) Compounds for use in the treatment of erbb2+ brain cancer
IN2015DN00515A (en)
MX2014015039A (en) Fbxo3 inhibitors.
HK1203054A1 (en) Dinuceloside polyphosphates for the treatment of pain
MX2015013755A (en) Pharmaceutical formulation for use in the treatment and/or prevention of restenosis.
PH12016501183A1 (en) Novel compound for treatment of severe hypoglycemia
PT2872176T (en) Carboranylporphyrins for use in the treatment of cancer
UA117567C2 (en) Galactagogue compositions based on phosphatidylserine
PH12016501184A1 (en) Novel compound for treatment of severe hypoglycemia
PH12016501182A1 (en) Novel compound for treatment of severe hypoglycemia
IN2014KN01772A (en)
PL2855475T3 (en) Alpha-carbolines for the treatment of cancer
IL234796B (en) Compounds for the treatment of ischemia-reperfusion-related diseases
MY184721A (en) Use of odiparcil in the treatment of a mucopolysaccharidosis
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
UA72478U (en) Use of polentar as frigoprotector
GB201223371D0 (en) Novel mucinase for use in therapy or prophylaxis
IN2012DE01204A (en) "shikhar technology"